Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

110.14
Delayed Data
As of 4:00pm ET
 -4.53 / -3.95%
Today’s Change
89.76
Today|||52-Week Range
177.93
+1.37%
Year-to-Date
Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
Jan 18 / Zacks.com - Paid Partner Content
3 Companies Whose Sales Could Double in 2017
Jan 07 / MotleyFool.com - Paid Partner Content
Merrimack (MACK) Goes Uphill: Is a Turnaround Likely?
Jan 17 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close114.67
Today’s open112.22
Day’s range108.62 - 113.84
Volume509,539
Average volume (3 months)484,527
Market cap$2.8B
Dividend yield--
Data as of 4:00pm ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)+29.86%
Earnings growth (this year)-63.63%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+59.74%
P/E ratioNM
Price/Sales1,272.01
Price/Book4.64

Competitors

 Today’s
change
Today’s
% change
RAREUltragenyx Pharmaceu...-1.16-1.66%
ENDPEndo International P...-0.56-4.34%
CBPOChina Biologic Produ...+0.43+0.40%
PBHPrestige Brands Hold...0.000.00%
Data as of 4:02pm ET, 01/20/2017

Financials

Next reporting dateMarch 20, 2017
EPS forecast (this quarter)-$3.70
Annual revenue (last year)$2.8M
Annual profit (last year)-$226.4M
Net profit margin-8,139.07%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark E. Pruzanski
Chief Financial Officer
Sandip Kapadia
Corporate headquarters
New York, New York

Forecasts


Search for Jobs